U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb ’s Application for Repotrectinib for the Treatment of Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer

Application based on results from the registrational TRIDENT-1 trial, in which repotrectinib demonstrated high response rates and durable responses in patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer If...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news